ArticleBMC medical imaging2025
Predicting preoperative lymph node metastasis in patients with high-grade serous ovarian cancer by using intratumoral and peritumoral radiomics: a retrospective cohort study.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOvarian cancer (OC) carries the worst prognosis among gynecologic cancers, with high-grade serous ovarian cancer (HGSOC) as its most common subtype. Cytoreductive surgery (tumor resection) is the cornerstone of OC treatment. However, controversy remains regarding whether lymphadenectomy should be performed during surgery; more than 30% of patients with OC undergo unnecessary lymphadenectomy, increasing surgical risks and prolonging postoperative recovery. By analyzing multidimensional imaging features, such as tumor morphology, texture, and density, radiomics can accurately quantify the biological characteristics of tumors. However, its application in OC needs to be explored further. This study aimed to explore radiomics' role in predicting lymph node metastasis risk in HGSOC.
methodsThis retrospective cohort analysis involved 273 participants from Qingdao University Affiliated Hospital and Rizhao People's Hospital, and they were categorized into the training, testing, and external validation groups. Imaging characteristics were derived from the tumor region of interest and its surrounding areas (1-5 mm), and radiomics scores were calculated for each region. This approach was employed for assessing the diagnostic performance of different regions and identify the optimal one. We constructed a risk prediction model that integrated imaging features of the optimal region with independent clinical risk factors.
resultsThe radiomic features of the tumor and its surrounding 3-mm extension region yielded area under the curve (AUC) values of 0.957 and 0.793 in the training and testing sets, respectively. After integrating the radiomic features of the tumor and its surrounding 3-mm extension region with clinical features, the AUC values in the training set, testing set, and external validation set were 0.971, 0.811, and 0.869, respectively, demonstrating strong predictive ability.
conclusionsThis study developed a model to assess lymph node metastasis likelihood in HGSOC patients. In the test and external validation cohorts, the model demonstrated excellent predictive performance. We believe the model can assist clinicians in identifying patients who are suitable for lymph node resection, thereby optimizing treatment decisions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.